At the news
? MIXEDIMPACT 7/10 PRESS-RELEASE filed Mar 10, 2026 at 06:33 ET
BioNTech announced that its co-founders, Ugur Sahin and Özlem Türeci, will establish an independent biotechnology company focused on next-generation mRNA innovations, transitioning from their leadership roles by end of 2026. BioNTech plans to contribute mRNA-related rights and technologies to the new venture in exchange for a minority stake, aiming to sharpen its own focus on late-stage immunomodulators, ADCs, and mRNA candidates in oncology.
- Co-founders Ugur Sahin and Özlem Türeci will launch a new independent biotech company focused on next-generation mRNA technologies.
- Leadership transition expected by end of 2026; BioNTech is conducting an executive search for successors.
- BioNTech will contribute mRNA-related rights and technologies to the new company in exchange for a minority stake, milestones, and royalties.
- Binding agreement expected by end of H1 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access